Vivet Therapeutics announces 2 presentations on its lead product, VTX-801, at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Chicago May 16-19, 2018. Dr. Gloria Gonzalez-Aseguinolaza, Vivet CSO & Head of the Gene Therapy Dept. at the Fundación para la Investigación Médica Aplicada (FIMA) located at CIMA, a leading research center in the field of Gene Therapy located in Pamplona, Spain, will present recent preclinical data on Vivet’s lead product, VTX-801, generated by FIMA and Vivet through their strategic collaboration. VTX-801 is an adeno-associated virus (AAV) containing Vivet’s proprietary mini-ATP7B copper transporter, which targets the liver to restore copper homeostasis in Wilson’s Disease. The 2 presentations (“Therapeutic Efficacy of VTX-801, an Optimized AAV Vector for the Treatment of Wilson’s Disease”/Abstract 534 and “Nonclinical Safety Evaluation of VTX-801, an AAV Vector for Treatment of Wilson’s Disease”/Abstract 849) will take place during the “Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II” session (Stevens Salon C, D – Thursday, May 17 5:15 PM) and the “Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases III” session (Stevens Salon C, D – Friday, May 18 5:45 PM) respectively. These data demonstrate VTX-801’s sustained long-term efficacy and safety in both wt and ko mice for the treatment of Wilson’s disease.
